Redhill Biopharma Ltd (STU:2RH0)
€ 0.431 0.029 (7.21%) Market Cap: 13.74 Mil Enterprise Value: 9.70 Mil PE Ratio: 0 PB Ratio: 4.59 GF Score: 50/100

Redhill Biopharma Ltd To Discuss The Opaganib Phase 2/3 COVID-19 Data Call Transcript

Oct 07, 2021 / 12:30PM GMT
Release Date Price: €164.8 (-0.48%)
Operator

Good day, and welcome to the RedHill Biopharma's webcast on the opaganib Phase II/III data. (Operator Instructions)

At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Gilead Raday, RedHill's Chief Operating Officer; and Dr. Mark Levitt, RedHill's Medical Director Oncology.

Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.

Alexandra Okmian
RedHill Biopharma Ltd. - Senior Business Development & IR Manager

This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to the business promotion and other efforts related to RedHill's commercialization activities and the initiation, timing, progress and results of RedHill's research, manufacturing, preclinical studies, clinical trials, marketing applications and approvals, if any, including the results and the clinical study of opaganib for the treatment of COVID-19.

These statements are only

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot